SEC Form 13F

RiverVest Venture Management LLC 13F Holdings

Inspect RiverVest Venture Management LLC's 2024-09-30 SEC 13F positions, public filing date, amendments and original receipt.

As of 2024-10-31T03:59:59.999Z

Report period
2024-09-30
Publicly available
2024-10-31
Reported value
$6,838,040
Positions
3

Disclosed positions

Reneo Pharmaceuticals, Inc.UnresolvedCommon$4,308,1742,534,220SHNone
Spruce Bioscience, Inc.UnresolvedCommon$1,394,4412,936,281SHNone
Xilio Therapeutics, Inc.XLOCommon$1,135,4251,441,444SHNone

Largest 50 positions by reported value; the filing may contain more positions.

How amendments affect these holdings

This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 2 positions lack a resolved ticker and 0 positions are put or call entries.

A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.

Quarter end and public filing date

Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.